Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

This study has been completed.
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
First received: January 9, 2004
Last updated: February 19, 2012
Last verified: February 2005

RATIONALE: The hormone testosterone may improve the libido (sex drive) in women. It is not yet known whether testosterone is effective in improving libido in female cancer survivors.

PURPOSE: This randomized phase III trial is studying how well low-dose testosterone works to improve libido in postmenopausal cancer survivors.

Condition Intervention Phase
Cancer Survivor
Sexual Dysfunction
Sexuality and Reproductive Issues
Unspecified Adult Solid Tumor, Protocol Specific
Drug: therapeutic testosterone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Supportive Care
Official Title: The Use of Low Dose Testosterone To Enhance Libido In Female Cancer Survivors: A Phase III Randomized, Placebo-Controlled, Double-Blind Crossover Study

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: April 2004
Detailed Description:



  • Determine the efficacy of low-dose testosterone, in terms of average intra-patient change in libido, in postmenopausal female cancer survivors with a decreased libido.


  • Determine the toxic effects of this drug in these patients.
  • Determine the levels of estrogen and testosterone and SGOT in patients reporting a decreased libido before and after treatment with this drug.
  • Determine whether increasing libido significantly positively affects pleasure from sexual activity in patients treated with this drug.
  • Determine the effect of this drug on vitality, general quality of life, and overall mood in these patients.

OUTLINE: This is a double-blind, placebo-controlled, randomized, crossover, multicenter study. Patients are stratified according to antidepressant medication use (yes vs no), age (under 50 vs 50 to 60 vs 61 to 70 vs over 70), tamoxifen or other selective estrogen receptor modulator use (yes vs no), and ovarian status (in place [natural menopause or hysterectomy] vs not in place [bilateral oophorectomy]). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive topical testosterone once daily for 4 weeks.
  • Arm II: Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.

Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.

Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months.

PROJECTED ACCRUAL: A total of 140 patients (70 per treatment arm) will be accrued for this study within 14 months.


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • History of cancer

    • No active disease
  • Currently has a sexual partner
  • Reports a decrease in sexual desire or libido and would like an intervention for it

    • Defined as a score of less than 8 on the numerical analogue scale
  • Hormone receptor status:

    • Not specified



  • See Menopausal status


  • Female

Menopausal status

  • Postmenopausal, defined as the following:

    • Surgically induced menopause OR absence of a period for at least 12 months (naturally or treatment-induced)

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • WBC ≥ 2,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 10 g/dL
  • No untreated anemia


  • SGOT ≤ 1.5 times upper limit of normal (ULN)
  • No known liver disease


  • Creatinine ≤ 1.5 times ULN
  • No renal dysfunction


  • No coronary artery disease
  • No congestive heart failure


  • No untreated hypothyroidism
  • No diabetes
  • No major depressive disorder requiring treatment


Biologic therapy

  • Not specified


  • Concurrent cytotoxic chemotherapy (e.g., tamoxifen or aromatase inhibitors) allowed

Endocrine therapy

  • No prior testosterone
  • No prior androgen agents for libido
  • Concurrent selective estrogen receptor modulators allowed
  • Concurrent vaginal estrogen allowed provided it was initiated ≥ 1 month ago and continued at the same dose during study participation


  • Concurrent radiotherapy allowed


  • No prior major pelvic surgery resulting in anatomical changes to the vaginal anatomy

    • Prior hysterectomy allowed


  • Concurrent antidepressants for postmenopausal mood or hot flashes allowed provided patient is on a stable dose that will not change within the next 8 weeks
  • No concurrent anticoagulants or propanolol

    • Concurrent anticoagulants for central or peripheral line maintenance (e.g., warfarin 1 mg daily or heparin flushes) allowed
  • No other concurrent treatment for decreased libido
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00075855

United States, Arizona
CCOP - Mayo Clinic Scottsdale Oncology Program
Scottsdale, Arizona, United States, 85259-5404
United States, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States, 32224
United States, Illinois
CCOP - Carle Cancer Center
Urbana, Illinois, United States, 61801
United States, Iowa
CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa, United States, 52403-1206
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, United States, 50309-1016
Siouxland Hematology-Oncology
Sioux City, Iowa, United States, 51101-1733
United States, Kansas
CCOP - Wichita
Wichita, Kansas, United States, 67214-3882
United States, Michigan
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, United States, 48106
United States, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905
United States, Nebraska
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, United States, 68106
United States, North Dakota
Medcenter One Health System
Bismarck, North Dakota, United States, 58501-5505
CCOP - Merit Care Hospital
Fargo, North Dakota, United States, 58122
United States, Ohio
CCOP - Dayton
Dayton, Ohio, United States, 45429
United States, Pennsylvania
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania, United States, 17822-2001
United States, South Dakota
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, United States, 57104
United States, Wisconsin
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, United States, 54301
Sponsors and Collaborators
North Central Cancer Treatment Group
Investigator: Charles L. Loprinzi, MD Mayo Clinic
Study Chair: Debra Barton, RN, PhD, AOCN, FAAN Mayo Clinic
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00075855     History of Changes
Other Study ID Numbers: CDR0000349426, NCCTG-N02C3
Study First Received: January 9, 2004
Last Updated: February 19, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
sexual dysfunction
unspecified adult solid tumor, protocol specific
sexuality and reproductive issues
cancer survivor

Additional relevant MeSH terms:
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Anabolic Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on July 05, 2015